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SUMMARY Chronic venous insufﬁciency frequently leads to 
ulceration. The exact pathophysiological mechanisms underlying 
the development of venous ulceration remain to be elucidated. One 
major etiological factor of the trophic changes is the phenomenon 
of leukocyte trapping. The aim of the study was to review the 
pathophysiological events culminating in venous ulceration, 
focusing primarily on the role of alterations in nitric oxide (NO) 
production. We establish the hypothesis that venous stasis in the 
microcirculation reduces the rate of shear stress on the endothelial 
cells, effectively resulting in a decrease in cellular levels of NO, 
a key event of enhanced adhesion molecule expression and 
subsequent massive neutrophil activation. A similar series of 
events is proposed to explain the ischemic-reperfusion tissue 
injury. Inducible NO (iNO) produced by the inﬂammatory cells 
causes free radical injury seen as a venous ulceration.
KEY WORDS venous ulceration; pathophysiology of venous 
ulcers; nitric oxide
INTRODUCTION
 Venous ulcers are chronic wounds due to 
chronic venous insufﬁciency (CVI) in the lower 
limbs. This pathophysiological state is the conse-
quence of sustained elevation of venous pressure 
in the macrocirculation of the affected leg due to 
valve incompetence. Chronic venous hypertension 
leads to secondary disorders of the microcircula-
tion and results in interstitial and skin damage (li-
podermatosclerosis and venous ulceration). How-
ever, the mechanisms underlying the development 
of venous ulceration remain to be elucidated. 
 Many theories have been advanced in the past 
to explain the sequence of events that give rise 
to venous ulceration. The simple concept that tis-
sue hypoxia leads to venous ulceration has been 
largely abandoned (1). In recent years attention 
has focused on the inﬂammatory events and the 
deleterious effects of white cells “trapped” in the 
microcirculation, which attend venous disease 
and development of venous ulceration (2). 
 The chronic inﬂammation in venous ulcers is 
similar to cellular events seen in ischemia-reper-
fusion injury, mainly increases in adhesion mol-
ecule expression, NO production and oxidant 
production (3).  
 By analogy with the sequence of events that oc-
cur during repeated ischemia-reperfusion injury in 
patients with venous hypertension, it is tempting to 
speculate a pathogenetic role of disturbed NO pro-
duction in the development of venous ulceration. 
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PATHOPHYSIOLOGY OF VENOUS 
ULCERS
 Congenital or acquired incompetence of valves 
in the superﬁcial or communicating veins or post-
thrombotic damage of valves in deep veins permits 
venous reﬂux. Furthermore, an obstruction of the 
venous outﬂow may lead to an increased resis-
tance and increased intravascular pressure. Mani-
festation of these disorders is the development of 
chronic hypertension in the venous macrocircula-
tion as well as in the capillaries and postcapillary 
venules. Venous stasis leads to a decrease in the 
level of shear stress and subsequent endothelial 
dysfunction, which is manifested in disturbed re-
leases of agents that regulate vasomotor function, 
trigger inﬂammatory processes, and affect hemos-
tasis (4,5). 
 Histopathologic features of the periulcer skin 
include perivascular inﬁltration of the capillaries 
of the papillary plexus with monocytes, macro-
phages and connective tissue proteins including 
ﬁbrin (6). These ﬁndings have focused attention 
on the chronic inﬂammation associated with ve-
nous ulcers. The phenomenon of leukocyte trap-
ping in the microcirculation and leukocyte seques-
tration is similar to the series of events following 
reperfusion of ischemic tissue that causes tissue 
damage. In venous ulcers, the ischemic event oc-
curs when the lower extremity is dependent and 
the normal arterial-venous pressure gradient is no 
longer present. There is blood stasis and effective 
loss of circulation. When the leg is elevated, circu-
lation is restored, and the inﬂammatory changes 
that occur with reperfusion worsen the injury.
Ischemia-reperfusion: cellular events
 During the reperfusion process after an ischem-
ic event secondary to lower extremity dependency 
in the setting of venous insufﬁciency, the endothe-
lial surface expresses adhesion molecules. In the 
initial stages of the adhesion process, P- or E-se-
lectin expressed on the endothelial cells binds to 
carbohydrates on the leukocyte surface (7). This 
interaction slows white blood cells and causes 
them to roll along the endothelial surface. At the 
same time activated leukocytes release reactive 
substances such as leukotrienes, interleukins and 
platelet activating factor (8). Other, subsequently 
expressed cell adhesion molecules including 
ICAM-1 and VCAM-1 then latch onto the integrin 
receptors and completely arrest white cells (7). In 
the second phase of leukocyte recruitment, activa-
tion of leukocytes as well as de novo expression 
of endothelial adhesion proteins and chemokines 
(e.g. monocyte chemoattractant protein-1, MCP-
1) promote leukocyte migration out of the blood 
vessel and into the interstitium (8,9). Activated 
leukocytes release toxic metabolites, proteolytic 
enzymes and free radicals, which cause tissue 
injury. 
 Repeated ischemia perfusion events potentiate 
the cycle of inﬂammatory cytokines, leukocyte mi-
gration, and protease and oxidant injury with loss 
of tissue perfusion and resultant tissue necrosis. 
Nitric oxide
 Nitric oxide (NO) is a structurally simple com-
pound that participates in a wide range of bio-
chemical reactions and evokes a variety of biologi-
cally relevant responses. It was ﬁrst discovered in 
1980 by Furchgott and Zawadzki as an endothe-
lium-derived relaxing factor (EDRF) (10). In 1987, 
NO was identiﬁed as a biologically active agent in 
EDRF (11). This ﬁnding was awarded Nobel Prize 
for Medicine and Physiology ﬁve years later.
 NO is produced from the precursor amino acid 
L-arginine by the enzyme NO synthase (NOS). 
NOS is known to be present in at least two iso-
forms. The ﬁrst, calcium-dependent isoform, is 
normally expressed constitutively in the tissues. 
It includes endothelial NOS (eNOS) in the vascu-
lar endothelial cells and neuronal NOS (nNOS) 
in peripheral nerves (12). The second isoform is 
calcium-independent, inducible isoform (iNOS) 
which is produced mainly in pathologic conditions 
(13). Constitutive NOS rapidly synthesizes small 
amounts of NO in response to increases of intra-
cellular calcium in pulsative manner. In contrast, 
iNOS is under transcriptional control whose ex-
pression can be induced in a wide range of cells 
and tissues by cytokines and other agents such as 
endotoxin (14,15). 
 Shear forces exerted on the endothelial sur-
face appear to modulate the release of NO (16). 
NO produced by endothelial cells is important in 
the regulation of the local blood ﬂow. It is now rec-
ognized as a key determinant of vascular health 
by regulating several physiologic effects, including 
vascular tone, vascular permeability, endothelial-
leukocyte interaction, cell proliferation, and the 
antithrombotic properties of the endothelium (17). 
Many studies have shown that NO plays a protec-
tive role in several models of inﬂammation includ-
ing ischemia-reperfusion by reducing leukocyte-
endothelial cell adhesion (18). These functions 
converge to maintain normal endothelial pheno-
type and an antithrombotic intravascular milieu.
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 NO produced by iNOS has been described to 
have beneﬁcial microbicidal, antiviral, antiparasit-
ic, and antitumoral effects (14) However, aberrant 
iNOS induction seems to be involved in the patho-
physiology of human diseases such as asthma, ar-
thritis, multiple sclerosis, colitis, psoriasis, chronic 
wounds, tumor development, transplant rejection, 
or septic shock (19). 
 High concentrations of NO are toxic and act 
as free radicals. Large amounts of NO produced 
by the induction of iNOS interact with oxygen free 
radicals derived from polymorphonuclear cells 
(PMNs) and macrophages to form peroxynitrite 
(20). NO, either alone or when combined with oth-
er oxygen or nitrous free radicals, results in tissue 
damage. 
 In addition, sufﬁcient amounts of NO are able to 
promote apoptotic cell death due to its damaging 
effects on DNA and the subsequent expression of 
the tumor suppressor gene, p53 (21,22).
Nitric oxide and wound healing
 NO is known to be synthesized in the wound, 
but its role in the healing process is only beginning 
to be deﬁned (23). The cellular sources of NO dur-
ing healing process are probably multiple and are 
not fully established although inﬂammatory cells 
such as macrophages and polymorphonuclear 
neutrophils have been shown to synthesize large 
amounts of NO (24). 
 In acute wound, iNOS predominates in the early 
stage where the wound environment is cytotoxic. 
Expression of iNOS at this time is consistent with 
the known effects of NO, such as vasodilatation 
(25), antimicrobial activity (26), and anti-platelet 
aggregation activity (27). 
 Thus, the expression of NO is important in the 
normal process of wound healing. We hypothe-
size that impaired production of NO is associated 
with disturbed wound healing in chronic wounds 
including chronic venous ulcers.
 
The role of nitric oxide in venous 
ulceration
 The increased capillary and venular diameter 
associated with CVI leads to a decrease in the 
level of shear stress in the affected vessels and 
to a diminished synthesis and release of NO from 
the vascular endothelium. Low endothelial NO 
bioavailability can upregulate VCAM-1 in the en-
dothelial cell layer (28). The expression of VCAM-
1, ICAM-1, and E-selectin plays a role in the initia-
tion of the inﬂammatory process. VCAM-1 binds 
monocytes and T lymphocytes, the ﬁrst step of 
invasion of the vessel wall by inﬂammatory cells 
(29). A reduction in NO results in the induction 
of MCP-1 expression that recruits mononuclear 
phagocytes (20).
 In the second phase, large amounts of NO 
produced by the induction of iNOS will interact 
with oxygen free radical derived from PMNs and 
macrophages to form peroxynitrite. Peroxynitrite 
is a potent oxidant that can attack many types of 
biological molecules and has strong oxidizing and 
cytotoxic properties causing tissue damage (30). 
Increased iNOS activity has been demonstrated in 
the skin of venous ulcer patients (31). NO, either 
alone or when combined with other oxygen or ni-
trous free radicals, could result in tissue damage 
associated with chronic venous ulcers. 
 In the presence of superoxide (O2), however, 
NO reacts extremely rapidly to produce the very 
reactive and toxic peroxynitrite (ONOO-), which 
subsequently decomposes into additional reactive 
intermediates (32). 
 In macrophages, activation of iNOS generates 
sufﬁcient amounts of NO to promote the apoptotic 
cell death (33). Induction of apoptosis could be an-
other mechanism through which NO produces its 
damaging effect in CVI tissues. 
FUTURE DIRECTIONS 
 The impaired endothelial function and impaired 
NO production in chronic venous ulcers are thought 
to be one of the possible mechanisms responsible 
for developing and delayed healing of venous ul-
cers. NO may represent a novel target molecule to 
circumvent many difﬁculties that occur throughout 
the healing process of chronic wounds. Because 
NO is a short-lived gas molecule, maintaining an 
effective level of NO at the wound site is an obvi-
ous problem for clinical therapy. In recent studies, 
Luo et al. have demonstrated that gene therapy 
of NOS or SOD is effective in restoring cutaneous 
NO levels and accelerating wound healing in dia-
betic mice (34).
CONCLUSION
 The hemodynamic and hemorheologic chang-
es, together with the pathologic changes in ves-
sel wall physiology, lead to venous ulceration. Im-
paired NO production manifested by a decrease in 
the levels of eNO and an increase in the levels of 
iNO have an important role in the development of 
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venous ulcers. Gene therapy strategies aimed at 
increasing NO or reducing superoxide levels may 
represent an effective means of reversing cutane-
ous NO deﬁciency at the wound site for refractory 
wound healing. Future preclinical studies are war-
ranted to optimize the designs and regimens be-
fore clinical trails can be conducted and  ultimate 
translation of basic science to clinical settings for 
human gene therapy. 
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